The present invention provides a fusion polypeptide comprising a biotin ligase enzyme fused to an immunoglobulin-binding bacterial protein, preferably wherein the immunoglobulin-binding bacterial protein is selected from Protein A, Protein G, Protein A/G and Protein L. The fusion polypeptide is preferably provided in combination with an antibody to which the immunoglobulin-binding bacterial protein can bind, and which combination is used for targeted proximity biotinylation.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
C07K 14/31 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
C07K 14/315 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
C12N 9/00 - Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
G01N 33/573 - Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
2.
SINGLE TUBE THERMAL PROTEOME PROFILING WITH UNIFORM PROGRESSION
The invention relates to a biomimetic microphone, a product comprising at least one biomimetic microphone, such as a hearing implant, wherein the hearing implant may comprise a cochlear implant, or a vibrating implant, or both, a method of operating a hearing implant, and a hearing implant computer program comprising instructions for operating the hearing implant.
The present invention relates to novel bi-functionalized trans-cyclooctenes of formula (1). It also relates to conjugates, compositions, medical uses of such compounds, and methods for producing such compounds as well as conjugates of such compounds.
C07C 69/74 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C07C 35/23 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with a hydroxy group on a condensed ring system having two rings
C07C 69/757 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
C07C 69/96 - Esters of carbonic or haloformic acids
C07C 271/34 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
C07D 311/16 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
The invention relates to a biomimetic microphone, a product comprising at least one biomimetic microphone, such as a hearing aid, wherein the hearing implant may comprise a cochlear implant, or a vibrating implant, or both, a method of operating a hearing implant, and a hearing implant computer program comprising instructions for operating the hearing implant.
H04R 1/34 - Arrangements for obtaining desired frequency or directional characteristics for obtaining desired directional characteristic only by using a single transducer with sound reflecting, diffracting, directing or guiding means
A system, a method and a computer program product are disclosed. The system is suitable for processing event-evoked physiological signals corresponding to a number of epochs of a trial, each epoch associated with an event involving a subset of a plurality of items. The system comprises a processor system configured to: calculate, a first value based on the epochs associated with a particular item of the plurality of items; calculate a second value based on the epochs not associated with the particular item; and select an item of the plurality of items as an attended-to item associated with the trial, based on the first value and the second value. The system/method/computer program product may have applications in the fields of health care, communications, gaming, control, rehabilitation, monitoring, neuromarketing, clinical assessments, objective assessments of healthy users (e.g. attention), etc. The system can be implemented using a computer or a distributed system such as cloud computing, with a dedicated brain-computer interface device.
The present invention relates to new carbohydrate derivatives ((O) and (l-oxide). The derivatives can be prepared via a method that involves direct amination. The derivatives can be used for various applications, for instance as surfactants.
C07C 215/10 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
C07C 229/12 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
C07C 229/22 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
C07C 235/06 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
C07C 235/12 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
C07C 291/04 - Compounds containing carbon and nitrogen and having functional groups not covered by groups containing nitrogen-oxide bonds containing amino-oxide bonds
C11D 1/52 - Carboxylic amides, alkylolamides or imides
The present invention relates to a new class of compounds based on a hexose featuring at least two 6-fluorides. The class is useful as inhibitors of 4,6-dehydratase enzymes. Such inhibitors are suitable for use as a medicament, for example for treating, preventing, or delaying cancer, tumor metastasis, inflammation, infections, or genetic disorders.
R; an excitation stage (130) comprising providing a radio frequency pulse to the target region, wherein the radio frequency pulse excites the element resulting in a transverse magnetization of the element; and a measurement stage (140) comprising detecting a signal from the element, wherein the measurement stage (140) is temporally arranged at an echo time TE after the radio frequency pulse, wherein the echo time TE is smaller than a transverse relaxation time of the element in the target region.
G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
in vitroin vitro method for fixating at least one cell, a fixative solution and a method for preparing same. The methods of the invention use or provide a fixative solution that is more stable than solutions from the prior art, and yield a better quality of isolated mRNA and proteins. In addition, excellent results are achieved when primary cells are fixated.
The present invention is in the field of a National Individual Floating Transportation Infrastructure (NIfTI) wherein floating vehicles can travel by magnetic levitation and propagation. The vehicles can travel at a controllable height above the existing, albeit modified, road infrastructure and at relatively high speeds.
A computer system comprising an artificial neural network comprising a plurality of units to learn a certain task, wherein the units are directionally connected and the network as a whole is organized to generate an output based on an input. The neural network is configured to calculate (303) an internal state value for each unit of the neural network, based on output values of the other units of the neural, weights associated with the directional connections in the neural network acting between pairs of units, and a perturbation value associated with each unit of the neural network, wherein the output value of a subset of units of the network corresponds to an input value of the neural network and the output values of a different subset of units comprise the output of the neural network.
The invention describes a method of reservoir computing and a reservoir computing system. A reservoir is provided which is operable to output an output signal in response to an input signal. The reservoir is provided with a reactor apparatus with a reactor chamber for receiving chemical substances and facilitating chemical reactions during a chemical process. An input layer is provided having at least one input node configured to receive the input signal; wherein the at least one input node is associated to one or more process parameters and/or a quantity of one or more chemical substances provided to the reactor chamber. Furthermore, a trained output layer is provided having at least one output node configured to output the output signal that is based on one or more readout outputs of the reservoir in response to the input signals.
The present invention is in the field of a compound for use as a medicament for treatment of tRNA deficiencies in living cells, a dosage comprising said compound, and an in vivo and in vitro method for treatment of tRNA deficiencies, as well as for prevention, mitigation of symptoms, and regeneration of cells.
The invention relates to a biomimetic microphone, a product comprising at least one biomimetic microphone, such as a hearing implant, wherein the hearing implant may com- prise a cochlear implant, or a vibrating implant, or both, a method of operating a hearing implant, and a hearing implant computer program comprising instructions for operating the hearing implant.
The present invention relates to novel bi-functionalized trans-cyclooctenes of formula (I). It also relates to conjugates, compositions, medical uses of such compounds, and methods for producing such compounds as well as conjugates of such compounds.
C07C 35/23 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with a hydroxy group on a condensed ring system having two rings
C07C 69/753 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of polycyclic acids
C07C 62/32 - Unsaturated compounds containing hydroxy or O-metal groups
C07C 69/757 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
C07C 69/96 - Esters of carbonic or haloformic acids
A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
C07C 271/34 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
C07D 311/16 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
C07H 15/252 - Naphthacene radicals, e.g. daunomycins, adriamycins
A bicycle simulator system (1), comprising a support base (2) having a front end (2a) configured to support a front wheel (Fw) of a bicycle (B), and a rear end (2b) configured to support a rear wheel (Rw) of the bicycle (B). A display device (5) is provided for arrangement in front of the support base (2), wherein a virtual reality, VR, processing system (6) is provided for communicative connection (7) to the display device (5). The VR processing system (6) is configured to: display a VR road environment (E) on the display device (5); detect a lateral position (P) of the bicycle (B) and a rider (R) thereon with respect to the support base (2); and change the VR road environment (E) being displayed in response to a detected change in the lateral position (P) of the bicycle and the rider (R).
A63B 21/005 - Exercising apparatus for developing or strengthening the muscles or joints of the body by working against a counterforce, with or without measuring devices using electromagnetic or electric force-resisters
The present invention provides a fusion polypeptide comprising a biotin ligase enzyme fused to an immunoglobulin-binding bacterial protein, preferably wherein the immunoglobulin-binding bacterial protein is selected from Protein A, Protein G, Protein A/G and Protein L. The fusion polypeptide is preferably provided in combination with an antibody to which the immunoglobulin-binding bacterial protein can bind, and which combination is used for targeted proximity biotinylation.
The present invention relates to the field of medicine. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Stargardt disease.
STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM (Netherlands)
STICHTING RADBOUD UNIVERSITEIT (Netherlands)
Inventor
Rijpkema, Mark
Heskamp, Sandra
Laverman, Peter
Derks, Yvonne Hendrika Wilhelmina
Lowik, Dennis Wilhelmus Petrus Maria
Abstract
The invention relates to a new class of compounds that can serve as prostate specific membrane antigen (PSMA) ligands, and to precursors to this class. The precursors have an amine that is available for functionalisation. Derivatives of the compounds are useful for imaging and therapy of cancer.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4406 - Non-condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
A61K 31/4427 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM (Netherlands)
STICHTING RADBOUD UNIVERSITEIT (Netherlands)
Inventor
Rijpkema, Mark
Heskamp, Sandra
Laverman, Peter
Derks, Yvonne Hendrika Wilhelmina
Löwik, Dennis Wilhelmus Petrus Maria
Abstract
The invention relates to a new class of compounds that can serve as prostate specific membrane antigen (PSMA) ligands, and to precursors to this class. The precursors have an amine that is available for functionalisation. Derivatives of the compounds are useful for imaging and therapy of cancer.
The present invention is in the field of a compound for use as a medicament for treatment of tRNA deficiencies in living cells, a dosage comprising said compound, and an in vivo and in vitro method for treatment of tRNA deficiencies, as well as for prevention, mitigation of symptoms, and regeneration of cells.
C12N 15/11 - DNA or RNA fragments; Modified forms thereof
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
C12N 9/00 - Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
A double network hydrogel including a polymer (A) having a persistence length between 10 and 1000 nm; a flexible polymer (B), wherein the persistence length is measured according to single molecule force microscopy measurement, wherein polymer (B) has an extended coil conformation at a first condition and a collapsed globular conformation at a second condition. Polymer (A) preferably is a polyisocyanate, while polymer (B) is a crosslinked flexible polymer like for example PNIPAM. A method for making a double network hydrogel.
A polymer hydrogel having a polymer formed by the crosslinking reaction of a polymeric unit A according to formula (I),
with a crosslinking unit B according to formula (II)
and water, wherein n=100-10,000, preferable 250-2500, more preferable 500-1500; m=independently 2-10, preferably 3 or 4; FG is a functional moiety that can be covalently coupled to the complementary functional moiety F1 or F2 of the crosslinking unit (B); k=0.01-0.05; h=0, 1 or 2; the spacer is an organic moiety, having a main chain comprising at least two functional moieties F1 and F2, wherein the length of the crosslinker in the extended conformation as determined by molecular modeling (including spacer and functional groups F1 and F2) is between 2.5 and 12 nm, or wherein the length is between 20 and 80 atoms.
C08G 61/04 - Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aliphatic carbon atoms
The present invention relates to a process for the preparation of oligo(alkylene glycol)-functionalized polyisocyanopeptides comprising the steps of functionalizing an isocyanopeptide with oligo-(alkylene glycol) side chains and subsequently polymerizing the oligo-alkylene glycol-functionalized isocyanopeptides. Several isocyanopeptides may be functionalized with various linear or non-linear oligo-(alkylene glycol) side chains having variable chain length. The alkylene glycol may be selected from the group consisting of ethylene-, propylene-, butylene- or pentylene glycol. Preferably, the isocyanopeptides are functionalized with at least three ethylene glycol side chains. The peptides may comprise L-amino acids, D-amino acids or D, L-amino acids. The obtained oligoalkylene-functionalized polyisocyanopeptides are a new class of materials with unique thermo-responsive properties.
G06K 9/62 - Methods or arrangements for recognition using electronic means
G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints
G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A process for making an oligo(alkylene glycol) functionalized co-polyisocyanopeptide, wherein the process includes the steps of: i) copolymerizing a first comonomer of an oligo(alkylene glycol) functionalized isocyanopeptide grafted with a linking group and a second comonomer of a non-grafted oligo(alkylene glycol) functionalized isocyanopeptide, wherein the molar ratio between the first comonomer and the second comonomer is 1:500 and 1:30 and ii) adding a reactant of a spacer unit and a cell adhesion factor to the copolymer obtained by step i), wherein the spacer unit is represented by general formula A-L-B, wherein the linking group and group A are chosen to react and form a first coupling and the cell adhesion factor and group B are chosen to react and form a second coupling, wherein the first coupling and the second coupling are independently selected from the group consisting of alkyne-azide coupling, dibenzocyclooctyne-azide coupling, oxanorbornmadiene-based-azide couplings, vinylsulphone-thiol coupling, maleimide-thiol coupling, methyl methacrylate-thiol coupling, ether coupling, thioether coupling, biotin-strepavidin coupling, amine-carboxylic acid resulting in amides linkages, alcohol-carboxylic acid coupling resulting in esters linkages and NHS-Ester (N-Hydroxysuccinimide ester)-amine coupling and wherein group L is a linear chain segment having 10-60 bonds between atoms selected from C, N, O and S in the main chain.
STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM (Netherlands)
STICHTING RADBOUD UNIVERSITEIT (Netherlands)
Inventor
Rowan, Alan Edward
Eksteen Akeroyd, Zaskia Hillet
Wilson, Christopher
Geutjes, Petrus Johannes
Feitz, Wouter F.J.
Oosterwijk, Egbert
Abstract
The invention relates to a process for making an oligo(alkylene glycol) functionalized co-polyisocyanopeptide, wherein the process comprises the steps of: i) copolymerizing - a first comonomer of an oligo(alkylene glycol) functionalized isocyanopeptide grafted with a linking group and - a second comonomer of a non-grafted oligo(alkylene glycol) functionalized isocyanopeptide, wherein the molar ratio between the first comonomer and the second comonomer is :500 and 1:30 and ii) adding a reactant of a spacer unit and a cell adhesion factor to the copolymer obtained by step i), wherein the spacer unit is represented by general formula A-L-B, wherein the linking group and group A are chosen to react and form a first coupling and the cell adhesion factor and group B are chosen to react and form a second coupling, wherein the first coupling and the second coupling are independently selected from the group consisting of alkyne-azide coupling, dibenzocyclooctyne-azide coupling, oxanorbornadiene-based-azide couplings, vinylsulphone-thiol coupling, maleimide-thiol coupling, methyl methacrylate-thiol coupling, ether coupling, thioether coupling, biotin- strepavidin coupling, amine-carboxylic acid resulting in amides linkages, alcohol- carboxylic acid coupling resulting in esters linkages and NHS-Ester (N- Hydroxysuccinimide ester)-amine coupling and wherein group L is a linear chain segment having 10-60 bonds between atoms selected from C, N, O and S in the main chain.
The present invention relates to protein constructs that comprise one or more peptides, proteins, factors, compounds or other components as further described herein that are linked to and/or are linked to each other via a helical polymeric backbone. The constructs of the invention are suitable for administration to a human or animal body and can be used for pharmaceutical purposes, for example, for immunotherapy, such as for treating cancer and for other immunological applications, as well as for other therapeutic, prophylactic and/or diagnostic purposes.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
C07K 14/74 - Major histocompatibility complex (MHC)
30.
Method for the preparation of high molecular weight oligo(alkylene glycol) functionalized polyisocyanopeptides
The present invention relates to a process for the preparation of oligo(alkylene glycol) functionalized polyisocyanopeptides comprising the steps of functionalizing an isocyanopeptide with oligo-(alkylene glycol) side chains and subsequently polymerizing the oligo-alkylene glycol functionalized isocyanopeptides. Several isocyanopeptide may be functionalized with various linear or non-linear oligo-(alkylene glycol) side chains having variable chain length. The alkylene glycol may be selected from the group consisting of ethylene-, propylene-, butylene- or pentylene glycol. Preferably the isocyanopeptides are functionalized with at least 3 ethylene glycol side chains. The peptides may comprise L aminoacids, D-aminoacids or D, L-aminoacids. The obtained oligoalkylene functionalized polyisocyanopeptides are a new class of materials with unique thermo-responsive properties.
The invention relates to method of detecting autoantibodies from patients suffering from rheumatoid arthritis. To this end, according to the invention, at least two peptide units are used of which at least one peptide unit comprises a part not derived from (pro)filaggrin, fibrin, fibrinogen, vimentin, cytokeratin 1 and cytokeratin 9, and which peptide unit comprises the motif XG, and a peptide unit comprising the motif XnonG, wherein X is a citrulline or an analogue thereof, and nonG is an amino acid other than glycine.
An apparatus, system, and method are disclosed for rebuilding only changed stripes of an offline member disk in a RAID array that is configured with redundancy and no hot standby disk. A work-in-progress (“WIP”) map tracks the changed stripes of the offline member disk prior to a reactivation and records the completion of the differential rebuilding (“DR”) process on the stripes. The DR process shortens the duration of a degraded mode of operation entered into by a logical drive formed when the RAID array experiences a member disk failure that results in one member disk being designated as offline.
patents
